207 related articles for article (PubMed ID: 31355457)
1. Modulation of μ-opioid receptor activation by acidic pH is dependent on ligand structure and an ionizable amino acid residue.
Meyer J; Del Vecchio G; Seitz V; Massaly N; Stein C
Br J Pharmacol; 2019 Dec; 176(23):4510-4520. PubMed ID: 31355457
[TBL] [Abstract][Full Text] [Related]
2. Agonist stimulation at human μ opioid receptors in a [(35)S]GTPγS incorporation assay: observation of "bell-shaped" concentration-response relationships under conditions of strong receptor G protein coupling.
Heusler P; Tardif S; Cussac D
J Recept Signal Transduct Res; 2016; 36(2):158-66. PubMed ID: 26466637
[TBL] [Abstract][Full Text] [Related]
3. Long-term antagonism and allosteric regulation of mu opioid receptors by the novel ligand, methocinnamox.
Zamora JC; Smith HR; Jennings EM; Chavera TS; Kotipalli V; Jay A; Husbands SM; Disney A; Berg KA; Clarke WP
Pharmacol Res Perspect; 2021 Dec; 9(6):e00887. PubMed ID: 34713624
[TBL] [Abstract][Full Text] [Related]
4. Phosphorylation of the mu-opioid receptor at tyrosine 166 (Tyr3.51) in the DRY motif reduces agonist efficacy.
Clayton CC; Bruchas MR; Lee ML; Chavkin C
Mol Pharmacol; 2010 Mar; 77(3):339-47. PubMed ID: 19959593
[TBL] [Abstract][Full Text] [Related]
5. Biased μ-opioid receptor agonists diversely regulate lateral mobility and functional coupling of the receptor to its cognate G proteins.
Melkes B; Hejnova L; Novotny J
Naunyn Schmiedebergs Arch Pharmacol; 2016 Dec; 389(12):1289-1300. PubMed ID: 27600870
[TBL] [Abstract][Full Text] [Related]
6. Chronic exposure to mu-opioid agonists produces constitutive activation of mu-opioid receptors in direct proportion to the efficacy of the agonist used for pretreatment.
Liu JG; Prather PL
Mol Pharmacol; 2001 Jul; 60(1):53-62. PubMed ID: 11408600
[TBL] [Abstract][Full Text] [Related]
7. Constitutive activity of the cannabinoid CB1 receptor regulates the function of co-expressed Mu opioid receptors.
Canals M; Milligan G
J Biol Chem; 2008 Apr; 283(17):11424-34. PubMed ID: 18319252
[TBL] [Abstract][Full Text] [Related]
8. Residues W320 and Y328 within the binding site of the μ-opioid receptor influence opiate ligand bias.
Hothersall JD; Torella R; Humphreys S; Hooley M; Brown A; McMurray G; Nickolls SA
Neuropharmacology; 2017 May; 118():46-58. PubMed ID: 28283391
[TBL] [Abstract][Full Text] [Related]
9. Selectivity of mu-opioid receptor determined by interfacial residues near third extracellular loop.
Bonner G; Meng F; Akil H
Eur J Pharmacol; 2000 Sep; 403(1-2):37-44. PubMed ID: 10969141
[TBL] [Abstract][Full Text] [Related]
10. Up-regulation of spinal mu-opioid receptor function to activate G-protein by chronic naloxone treatment.
Narita M; Mizoguchi H; Nagase H; Suzuki T; Tseng LF
Brain Res; 2001 Sep; 913(2):170-3. PubMed ID: 11549382
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of forebrain μ-opioid receptor signaling by low concentrations of rimonabant does not require cannabinoid receptors and directly involves μ-opioid receptors.
Zádor F; Otvös F; Benyhe S; Zimmer A; Páldy E
Neurochem Int; 2012 Aug; 61(3):378-88. PubMed ID: 22613132
[TBL] [Abstract][Full Text] [Related]
12. A6V polymorphism of the human μ-opioid receptor decreases signalling of morphine and endogenous opioids in vitro.
Knapman A; Santiago M; Connor M
Br J Pharmacol; 2015 May; 172(9):2258-72. PubMed ID: 25521224
[TBL] [Abstract][Full Text] [Related]
13. A low pKa ligand inhibits cancer-associated pain in mice by activating peripheral mu-opioid receptors.
Baamonde A; Menéndez L; González-Rodríguez S; Lastra A; Seitz V; Stein C; Machelska H
Sci Rep; 2020 Oct; 10(1):18599. PubMed ID: 33122720
[TBL] [Abstract][Full Text] [Related]
14. CB1 receptor-independent actions of SR141716 on G-protein signaling: coapplication with the mu-opioid agonist Tyr-D-Ala-Gly-(NMe)Phe-Gly-ol unmasks novel, pertussis toxin-insensitive opioid signaling in mu-opioid receptor-Chinese hamster ovary cells.
Cinar R; Szücs M
J Pharmacol Exp Ther; 2009 Aug; 330(2):567-74. PubMed ID: 19448142
[TBL] [Abstract][Full Text] [Related]
15. Internalization and recycling of human mu opioid receptors expressed in Sf9 insect cells.
Chen LE; Gao C; Chen J; Xu XJ; Zhou DH; Chi ZQ
Life Sci; 2003 May; 73(1):115-28. PubMed ID: 12726892
[TBL] [Abstract][Full Text] [Related]
16. Stimulation of guanosine-5'-o-(3-[35S]thio)triphosphate binding in digitonin-permeabilized C6 rat glioma cells: evidence for an organized association of mu-opioid receptors and G protein.
Alt A; McFadyen IJ; Fan CD; Woods JH; Traynor JR
J Pharmacol Exp Ther; 2001 Jul; 298(1):116-21. PubMed ID: 11408532
[TBL] [Abstract][Full Text] [Related]
17. Mutation of human mu opioid receptor extracellular "disulfide cysteine" residues alters ligand binding but does not prevent receptor targeting to the cell plasma membrane.
Zhang P; Johnson PS; Zöllner C; Wang W; Wang Z; Montes AE; Seidleck BK; Blaschak CJ; Surratt CK
Brain Res Mol Brain Res; 1999 Oct; 72(2):195-204. PubMed ID: 10529478
[TBL] [Abstract][Full Text] [Related]
18. Naloxone activation of mu-opioid receptors mutated at a histidine residue lining the opioid binding cavity.
Spivak CE; Beglan CL; Seidleck BK; Hirshbein LD; Blaschak CJ; Uhl GR; Surratt CK
Mol Pharmacol; 1997 Dec; 52(6):983-92. PubMed ID: 9415708
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and pharmacological studies of new hybrid derivatives of fentanyl active at the mu-opioid receptor and I2-imidazoline binding sites.
Dardonville C; Fernandez-Fernandez C; Gibbons SL; Ryan GJ; Jagerovic N; Gabilondo AM; Meana JJ; Callado LF
Bioorg Med Chem; 2006 Oct; 14(19):6570-80. PubMed ID: 16797997
[TBL] [Abstract][Full Text] [Related]
20. Opioid-induced regulation of gene expression in PC12 cells stably transfected with mu-opioid receptor.
Zarnegar P; Persson AI; Ming Y; Terenius L
Neurosci Lett; 2006 Apr; 396(3):197-201. PubMed ID: 16377088
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
